| Name | Title | Contact Details |
|---|---|---|
Ashley Taylor |
General Counsel | Profile |
Alyssa Boss |
Executive Vice President and General Counsel | Profile |
div#n2-ss-2{width:1200px;}div#n2-ss-2 .n2-ss-slider-1{position:relative;}div#n2-ss-2 .n2-ss-slider-background-video-container{position:absolute;left:0;top:0;width:100%;height:100%;overflow:hidden;}div#n2-ss-2 .n2-ss-slider-2{position:relative;overflow:...
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
Coldstar International Corp is a Piney Flats, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. Knight Therapeutics' shares are expected to begin trading on the TSX-V on March 3, 2014 under the symbol GUD.
It Health Track Inc is a Buffalo, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.